Main Directory
Articles 2591
CME 2
eCommerce 0
Medical Web Sites Directory 93
Podcasts 94
Web Design and Hosting 2




Nut Allergies Foremost in Pediatric Anaphylaxis
Link ID 8244
Title Nut Allergies Foremost in Pediatric Anaphylaxis
Url http://www.medscape.com/viewarticle/579687?src=rss
Description A review of anaphylaxis episodes in children shows that most reactions occur at home, most are triggered by peanuts or cashews, and treatment is often delayed. Reuters Health Information
Category Articles > Allergy and Clinical Immunology
Keywords
Date Aug 30, 2008
Contact Name
Email
Write a Review   Add to My Favorite   Refer it to Friend   Report Broken Link  

Average Visitor Rating: 0.00 (out of 5)
Number of ratings: 0 Votes
Visitor Rating

 Other links at Articles > Allergy and Clinical Immunology
1. Helicobacter pylori May Protect Children From Asthma
  Recent data suggest that the bacteria that causes stomach ulcer may, at the same time, protect children from asthma.
Expert Review of Clinical Immunology
Category:   Articles > Allergy and Clinical Immunology


2. Safety of High vs Recommended Doses of Anti-TNF-Alpha Therapy Reviewed
  Recommended doses of anti-tumor necrosis factor-alpha for rheumatoid arthritis did not increase the risk for serious adverse events, but high-dose therapy increased the risk for serious infections. Medscape Medical News
Category:   Articles > Allergy and Clinical Immunology


3. FDA Cautions Against Swallowing Tiotropium and Formoterol Capsules
  Tiotropium bromide (Spiriva) and formoterol fumarate (Foradil) capsules contain inhalation powder for delivery to the lungs and should only be administered through an inhalation device. Medscape Medical News
Category:   Articles > Allergy and Clinical Immunology


4. Integrative Medicine: Sorting Fact From Fiction
  Kenneth R. Pelletier, MD, PhD, Clinical Professor of Medicine at the University of Arizona School of Medicine and the University of California School of Medicine, describes evidence-based CAM.
Medscape General Medicine
Category:   Articles > Allergy and Clinical Immunology


5. Encouraging Phase 2b Results With Oral Laquinimod in MS
  Results of a phase 2b trial of laquinimod, an investigational oral treatment for MS, showed the higher dose of 0.6 mg/day was well tolerated and significantly reduced disease activity on MRI. Phase 3 trials are under way. Medscape Medical News
Category:   Articles > Allergy and Clinical Immunology




Home      New Listings      Hot Listings      Top Rated      Editor Pick      Add a Listing      Update a Listing      Get Rated      Upgrade a Listing
Valid XHTML 1.0 Transitional   Valid CSS